Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TPH1 | P17752 | 1/20 | 0.32 |
| ▸ | TPH2 | Q8IWU9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16544605 | 0.80 | GRIN1 (0.40) | GRIN1GRIN2BKDM4EALDH1A1HPGD | |
| SCHEMBL16624116 | 0.77 | GRIN1 (0.36) | GRIN1GRIN2BKDM4EALDH1A1HPGD | |
| SCHEMBL16422674 | 0.75 | GRIN1 (0.35) | GRIN1GRIN2BKDM4ETSHRMCHR1 | |
| SCHEMBL16544606 | 0.73 | GRIN1 (0.37) | GRIN1GRIN2BKDM4EALDH1A1HPGD | |
| SCHEMBL16422753 | 0.72 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL18033563 | 0.72 | GRIN1 (0.35) | GRIN1GRIN2BMCHR1 | |
| SCHEMBL17993842 | 0.72 | GRIN1 (0.33) | GRIN1GRIN2B | |
| SCHEMBL16544604 | 0.71 | GRIN1 (0.36) | GRIN1GRIN2BTSHRMCHR1MAPK1 | |
| SCHEMBL16544621 | 0.71 | GRIN1 (0.36) | GRIN1GRIN2BTSHRMCHR1 | |
| SCHEMBL3517522 | 0.71 | CSNK1E (0.35) | KDM4EALDH1A1HPGDTLR7TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | GRIN1 1068/4885GRIN2B 1695/4885KDM4E 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.